Trimethobenzamide hydrochloride en es it fr

Trimethobenzamide hydrochloride Brand names, Trimethobenzamide hydrochloride Analogs

Trimethobenzamide hydrochloride Brand Names Mixture

  • Alphasel tablets (calcium phosphate [dibasic] + cobalt sulfate + D-alpha tocopheryl acetate + selenium sulfide)
  • Previte (neomycin sulfate + selenium sulfide + streptomycin sulfate + vitamin A + vitamin D + vitamin E + vitamin K1)

Trimethobenzamide hydrochloride Chemical_Formula

C14H12N6O

Trimethobenzamide hydrochloride RX_link

No information avaliable

Trimethobenzamide hydrochloride fda sheet

Trimethobenzamide hydrochloride msds (material safety sheet)

Trimethobenzamide_hydrochloride MSDS

Trimethobenzamide hydrochloride Synthesis Reference

No information avaliable

Trimethobenzamide hydrochloride Molecular Weight

280.285 g/mol

Trimethobenzamide hydrochloride Melting Point

No information avaliable

Trimethobenzamide hydrochloride H2O Solubility

No information avaliable

Trimethobenzamide hydrochloride State

Solid

Trimethobenzamide hydrochloride LogP

2.759

Trimethobenzamide hydrochloride Dosage Forms

Intravenous (loading dose of 12 to 24 micrograms/kg over 10 minutes followed by a continuous infusion of 0.05 to 0.2 micrograms/kg per minute, adjusted according to response)

Trimethobenzamide hydrochloride Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF).

Trimethobenzamide hydrochloride Pharmacology

Levosimendan is a new Ca2+-sensitizing inotropic agent. Ca2+ sensitizers represent a new class of inotropic agents, which overcome the disadvantages associated with currently available inotropic agents in as they are not associated with an increased risk of arrhythmias, cell injury and death due to Ca2+ overload in myocardial cells; they do not increase the activation energy; and they have the potential to reverse contractile dysfunction under pathophysiologic conditions, such as acidosis or myocardial stunning. Levosimendan has not been approved for use in the U.S. or Canada.

Trimethobenzamide hydrochloride Absorption

The bioavailability of oral levosimendan is 85 ± 6% in healthy volunteers and 84 ± 4% in patients.

Trimethobenzamide hydrochloride side effects and Toxicity

No information avaliable

Trimethobenzamide hydrochloride Patient Information

No information avaliable

Trimethobenzamide hydrochloride Organisms Affected

Humans and other mammals